Anti-aging drug cocktail boosts mouse lifespan by 30 percent, offers hope for human longevity
Max Planck Institute for Biology of Ageing
in Germany has revealed that a combination of two existing drugs—rapamycin and trametinib—can extend the lifespan of mice by up to 30 percent. Not only did the mice live significantly longer, but they also remained healthier in old age, showing reduced inflammation, delayed tumour growth, and better overall physical function. This discovery could mark a major step forward in the pursuit of anti-ageing treatments for humans, offering hope that ageing-related decline can be slowed or even partially reversed in the future.
What is the drug combination that boosts the lifespan of mice
Rapamycin and trametinib
are both known drugs primarily used in cancer treatment. Rapamycin has been used to prevent organ rejection in transplant patients and has shown life-extending properties in animals. Trametinib, while less studied in larger animals, previously extended the lifespan of fruit flies. Scientists administered these drugs individually and in combination to hundreds of mice from the age of six months, then tracked their health and longevity. The combination therapy produced the most remarkable effects, with median lifespan increases of 34.9 percent in female mice and 27.4 percent in males.
Drug Cocktail improved health, not just lifespan
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Giao dịch CFD với công nghệ và tốc độ tốt hơn
IC Markets
Đăng ký
Undo
Importantly, the mice receiving the combination therapy did not merely live longer—they lived better. The treated animals experienced fewer age-related conditions such as liver and spleen tumours, and displayed significantly reduced inflammation in the brain, kidneys, muscles and spleen. They also retained more mobility and exhibited improved heart function. These results suggest that the treatment helps maintain a higher quality of life throughout old age, a key goal in the field of
longevity research
.
Why this matters for humans
Although these findings are based on animal models, they carry significant implications for human health. Both rapamycin and trametinib are already approved for medical use in humans in the United States and European Union, which could accelerate the path toward clinical trials for anti-ageing purposes. The fact that the combination targets different points in the same cellular pathway—the Ras/Insulin/TOR network—suggests a sophisticated synergy that enhances the benefits of each drug while limiting side effects. This gives scientists a strong foundation to begin evaluating their effectiveness in human ageing.
Caution and next steps
While the results are promising, researchers urge caution before assuming similar effects will be seen in people. Human biology is far more complex, and long-term use of these drugs could carry risks that are not evident in animal studies. Geneticist Linda Partridge, co-senior author of the study, emphasised that the goal is not necessarily to extend human lifespan dramatically, but to improve the quality of later life. Further studies and eventual human trials will be necessary to determine who might benefit and how best to apply the treatment.
The future of anti-ageing research
This study adds to a growing body of evidence suggesting that ageing can be manipulated through targeted medical interventions. As scientific understanding of cellular ageing deepens, the potential for developing treatments that slow or modify the ageing process becomes more tangible. With further research, the dream of living not just longer, but healthier lives into old age may one day become a reality for many.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
39 minutes ago
- Time of India
‘Fit for discharge, none to care': IMH holds recovered patients; Mental Healthcare Act mandates family reintegration
HYDERABAD: Although around 90 psychiatric patients at the Institute of Mental Health (IMH), Erragadda, have recovered and are deemed fit for reintegration into the community, many continue to remain in the hospital's discharge and cure (DC) ward. Doctors at the IMH report making 25 to 30 phone calls daily to the families of such patients, but to no avail. Relatives or next of kin often refuse to take them back, despite medical clearance. One such case involves a 45-year-old man from Sirpur who was admitted with bipolar affective disorder (BPAD) in December 2023 and declared fit for discharge in April 2024. However, the father of a 15-year-old boy is now being abandoned by his family. A month ago, he also developed a fever and subsequently suffered paralysis. You Can Also Check: Hyderabad AQI | Weather in Hyderabad | Bank Holidays in Hyderabad | Public Holidays in Hyderabad 'During his admission, his relatives came along, but now they claim it is his son's responsibility to bring him home. Although his psychiatric condition has improved, he currently has slurred speech (difficulty to pronounce words clearly) and an abnormal gait (change in walking pattern). He needs neurological treatment, but the family refuses to accept him,' said Dr Vivaswan Boorla, psychiatrist at IMH. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like For the chosen ones! 4&5 Bed Condominiums at Financial District, Hyd Sumadhura Group Learn More Undo On average, patients are recommended for discharge within three to four months, unless they have a chronic mental illness, in which case treatment typically lasts six to seven months. Most of the patients suffer from conditions such as schizophrenia, bipolar disorder, and other psychological illnesses. OVERUSE OF HOSP RESOURCES Telangana currently has two mental health review boards (MHRBs), which oversee discharge procedures via dedicated committees. While some recovered patients have been placed in care homes run by non-profits, this is only permitted through court orders. The situation is also contributing to the overuse of hospital resources and adding strain to IMH's 600-bed capacity. 'Beds and other resources continue to be occupied by patients who are already fit for discharge, even as new patients are admitted regularly. This often results in a shortage of space and puts additional pressure on the hospital staff,' said a senior doctor. Moreover, due to extended stays, many recovered patients in the DC ward begin to develop general health issues such as fever, cough, hypertension, and diabetes. 'These patients need to be taken to specialists at Osmania General Hospital (OGH) and other facilities, usually accompanied by a staff member in an ambulance. This adds further pressure on our staff,' the doctor added. Several of these patients were also taken ill during the food poisoning incident at IMH in early June. Citing the Mental Healthcare Act 2017, IMH superintendent Dr Anitha Rayirala emphasised that the law mandates the reintegration of recovered psychiatric patients into society. She added that the primary aim of the revised Act was to uphold the rights of individuals with mental illness, who were frequently abandoned in the past. 'The patients in DC wards have been granted the status of free citizens on court orders. Yet, there remains a widespread belief among family members that these individuals are still unwell, even when they are stable and doing well post-treatment. Another issue is that families often stop administering medication after discharge, leading to relapse. Family Unwilling A 46-year-old man from Pedadapally was admitted to the IMH in June 2019 following a magistrate's order and was declared fit for discharge in October 2020. According to doctors, the patient had discontinued his psychiatric medication on his own, claiming he was asymptomatic and no longer required treatment. However, due to his history of aggression and the potential risk he poses to his elderly parents, particularly in light of his mother's medical condition and his father's caregiving responsibilities, the family has expressed their unwillingness and inability to take him back home post-discharge. Fears Of Relapse In another case, a 36-year-old man from Mancherial diagnosed with bipolar affective disorder (BPAD) was admitted to the IMH in September 2024 and declared fit for discharge two months later. Despite repeated calls, his family members have expressed reluctance to take him home, citing fears of a potential relapse. While they assured the patient over the phone that they would visit soon, they have since informed the doctors that they do not intend to come.
Time of India
an hour ago
- Time of India
Need a testosterone boost? New study suggests trying weight-loss drugs like Ozempic
We're circling back to the age-old idea of hitting two birds with one stone! The medication that's widely prescribed to manage diabetes and used for weight loss as well – is now showing promise to offer some more exceptional health perks. Recent research suggests that GLP‑1 receptor agonists, like Ozempic, Wegovy, Mounjaro, and Trulicity, might offer an unexpected hormonal benefit. A recently presented ENDO 2025 study tracked 110 men over 18 months, revealing a remarkable rise in testosterone from 53% to 77% of normal levels, alongside about 10% average weight loss. These findings hint that by targeting fat reduction, insulin resistance, inflammation, and estrogen-to-testosterone conversion, these drugs could offer a dual boost for metabolic and men's health. Read on to know more. The GLP‑1–Testosterone breakthrough GLP‑1 receptor agonists – such as semaglutide (Ozempic/Wegovy), dulaglutide (Trulicity), and tirzepatide (Mounjaro/Zepbound) – work by mimicking the gut hormone GLP‑1 to suppress appetite, slow digestion, and improve insulin secretion. Now, testosterone is a hormone that fuels male sex drive and erectile function and influences everything from bone density and muscle mass to fat distribution, red blood cell production, mood, and energy levels. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like นี่อาจเป็นโอกาสทองที่ดีที่สุดในรอบ 5 ปีสำหรับการเทรดทองคำ IC Markets อ่านเพิ่มเติม Undo Unfortunately, testosterone levels naturally decline with age. Older men may feel more tired and grouchy, and less interested in sex. Not to mention the hair loss, bone fractures, and weight gain around the waist that often accompany low T. Luckily, there are ways to naturally boost testosterone. Exercise, especially strength training, a healthy diet, stress reduction, adequate sleep, and weight management, particularly for those who are overweight, are just a few. This new study highlights another tool that may help elevate these levels — Ozempic and other GLP-1 drugs. Endocrinology fellow Dr. Shellsea Portillo Canales and the research team analyzed the records of 110 adult men with obesity or Type 2 diabetes taking the weight-loss medications semaglutide (Wegovy), dulaglutide (Trulicity), or tirzepatide (Zepbound) but not participating in testosterone or hormonal therapy. These three drugs mimic the effects of GLP-1, a natural hormone in the body that regulates blood sugar and appetite, often leading to lower blood sugar and weight loss. At the ENDO 2025 conference , the team shared data showing men on these drugs experienced ~10% weight loss and significant testosterone increases (from 53% to 77% of normal) over 18 months. Mechanisms include reduced aromatase in shrinking fat, improved insulin sensitivity, and lower systemic inflammation – key drivers supporting testosterone production. The convincing evidence A 2025 meta-analysis (n=680) of seven GLP‑1 RA trials found a pooled increase in total testosterone of 1.39 ng/mL, with parallel gains in free testosterone, LH, FSH, weight loss, and HbA1c reduction. Liraglutide (Saxenda) was observed to restore gonadotropin signaling and improve testosterone in obese men, without the hormonal axis suppression typical of testosterone replacement therapy. However, a 2021 cohort in men with type 2 diabetes (n=51) showed only modest testosterone increases, primarily in men whose baseline testosterone was under 320 ng/dL or had ≥1% HbA1c reduction, reinforcing the importance of weight loss and insulin control. How does weight impact testosterone levels in males? In men, weight, particularly excess body fat, is inversely related to testosterone levels. Increased body fat, especially around the abdomen, is associated with lower testosterone, while weight loss, particularly through lifestyle changes, can lead to increased testosterone levels. As per research , weight loss can enhance testosterone levels because excess body fat contains the enzyme aromatase, which converts testosterone into estrogen. As reported by the NY Post, Dr. Shellsea Portillo Canales, an endocrinology fellow at SSM Health St. Louis University Hospital in Missouri, said, 'While it is well-known that weight loss from lifestyle changes or bariatric surgery increases testosterone levels, the impact that anti-obesity medications may also have on these levels has not been widely studied,' adding, 'Our study is among the first to provide compelling evidence that low testosterone can be reversed with the use of commonly prescribed anti-obesity medications. ' Portillo Canales also said, 'Results from this study show that there is a direct correlation between the use of anti-obesity medications and testosterone levels,' adding, 'Doctors and their patients can now consider this class of medications not only for the treatment of obesity and to control blood sugar, but also to benefit men's reproductive health.' The way ahead Although initial findings from ENDO 2025 and earlier trials are encouraging, longer randomized controlled trials (RCTs) are essential to confirm direct effects on fertility, muscle mass, mood, and safety of GLP‑1 therapies. If you're considering a testosterone boost without traditional hormone therapy, GLP‑1 agents like Ozempic may offer a compelling path: addressing weight, metabolic health – and testosterone – together. Talk to your endocrinologist to explore whether this novel approach fits your needs and goals. Always approach treatment under medical guidance – monitoring weight, hormones, metabolic health, fertility, and side effects. Study suggests digital apps can help chronic pain sufferers
Time of India
an hour ago
- Time of India
NASA warns! 280-foot asteroid 2025 MA90 to make close Earth flyby today at 20,263 mph; here's what you must know
Source: BBC An asteroid the size of a building, officially named asteroid 2025 MA90 , is making a close approach to Earth, drawing global attention from scientists and space agencies. Though the flyby poses no threat, it offers a valuable opportunity to study how such near-Earth objects (NEOs) behave. With NASA confirming the asteroid's safe distance and trajectory, and ISRO expressing renewed interest in planetary defence strategies, the event highlights the importance of early detection and international cooperation. As space agencies track and prepare for future events like Apophis 2029, the flyby of 2025 MA90 reminds us that cosmic vigilance is essential. NASA's asteroid 2025 MA90 to flyby today: Date, speed and distance An asteroid nearly the size of a city building is heading toward Earth, sparking interest but not alarm among scientists. Known as asteroid 2025 MA90, this space rock is being closely monitored as it prepares for a safe flyby on July 15. Measuring approximately 280 feet across and traveling at an impressive 20,263 miles per hour, MA90 is expected to pass by Earth at a distance of about 4 million kilometers. Though the approach is relatively close in cosmic terms, NASA confirms there is no risk of impact. The event serves as a reminder of our planet's vulnerability—and our increasing readiness. According to NASA, asteroid 2025 MA90 is classified as a member of the Aten group of asteroids—a class of near-Earth objects that orbit the Sun and sometimes cross Earth's orbit. However, this particular asteroid does not meet the criteria to be considered potentially hazardous. For an object to qualify as hazardous, it must be at least 85 meters wide and come within 7.4 million kilometers of Earth. While MA90 meets the size threshold, its projected flyby distance of approximately 4,020,000 kilometers places it safely outside the danger zone. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Get ₹2Cr life cover@ ₹700 p.m. ICICI Pru Life Insurance Plan Get Quote Undo Why tracking close approaches of asteroids still matters NASA's scientists continue to track the asteroid's trajectory for any changes, as even minor orbital shifts can affect long-term calculations. Nevertheless, this flyby offers a valuable opportunity for astronomers to study its movement, composition, and behavior in more detail using ground-based and radar observations. Though 2025 MA90 is not a threat, the incident reflects why tracking near-Earth objects (NEOs) is crucial for planetary defence. Even objects that miss Earth can reveal critical data about asteroid orbits, spin rates, and composition. These insights are vital for preparing for potential future threats. NASA and other space agencies around the world maintain extensive monitoring systems to catalog thousands of such asteroids, identifying any that may warrant further observation or mitigation strategies. This proactive approach aims to ensure that humanity is never caught off guard by a surprise impact. ISRO eyes Apophis 2029 and global planetary defence efforts While the focus now is on MA90, India's space agency ISRO has its eyes on a much larger and more complex challenge—the anticipated 2029 flyby of asteroid Apophis. This massive near-Earth object, measuring over 1,200 feet in diameter, will pass alarmingly close to Earth, within a distance of about 32,000 kilometers—closer than many satellites. ISRO Chairman S. Somanath has stressed the importance of collaborative global action to address such cosmic threats. He advocates for deeper cooperation between ISRO, NASA, ESA (European Space Agency), and JAXA (Japan Aerospace Exploration Agency). Together, these agencies can lead planetary defence missions that include impact deflection tests and potentially even asteroid landings. ISRO is reportedly developing missions that could involve landing on an asteroid, a bold step that would allow scientists to study their surfaces and structure directly. Asteroid MA90 flyby underscores the urgency of global planetary defence The peaceful flyby of asteroid 2025 MA90 should not overshadow the growing urgency in space science to build robust defence strategies. With the increasing detection of NEOs, the global community recognizes that Earth is not immune to cosmic hazards. Events like the Chelyabinsk meteor in 2013 have shown how even small asteroids can cause significant damage. Thus, every close encounter becomes both a warning and a learning opportunity. Also Read| Shubhanshu Shukla to return Earth after historic ISS mission; know what he achieved through space experiments
